Table 3 Correlation of ARK5 intracellular localization in RCC with clinicopathological parameters

Gender

Fisher Exact Test

0.39

 Male

10 (52.63%)

24 (66.7%)

 Female

9 (47.36%)

12 (33.3%)

Histological type clear

10 (52.6%)

19 (52.8%)

Chi square

0.67

 Papillary

2 (10.5%)

5 (13.9%)

 Chromophobe

5 (26.3%)

11 (30.6%)

 Others

2 (10.5%)

1 (2.8%)

Grade

 1

8 (42.1%)

4 (11.1%)

Chi-square

0.039*

 2

7 (36.8%)

14 (38.9%)

 3

2 (10.5%)

12 (33.3%)

 4

2 (10.5%)

6 (16.7%)

Apoptosis

3.05 ± 0.91

2.19 ± 0.71

Mann–Whitney

0.001**

Mitosis

2.4 ± 0.9

3.1 ± 1.2

Mann–Whitney

0.027*

Tumour extent

 T1

11 (57.9%)

6 (16.7%)

Chi-square

0.011*

 T2

6 (31.6%)

15 (41.7%)

 T3

2 (10.5%)

13 (36.1%)

 T4

0 (00%)

2 (5.6%)

LN

 Negative

19 (100%)

34 (94.4%)

Fisher Exact Test

0.54

 Positive

0 (00%)

2 (5.6%)

Stage

 I

11 (57.9%)

6 (16.7%)

Chi square

0.009*

 II

6 (31.6%)

14 (38.9%)

 III

2 (10.5%)

14 (38.9%)

 IV

0 (00%)

2 (5.6%)

Response to chemotherapy

 No

2 (10.5%)

11 (30.6%)

Chi-square

0.014*

 Partial

8 (42.1%)

17 (47.2%)

 complete

5 (26.3%)

1 (2.8%)